|
|
|
INTERNATIONAL APPLICATION PUBLISHED
UNDER THE PATENT
COOPERATION TREATY (PCT)
|
| (12) INTERNATIONAL APPLICATION
PUBLISHED UNDER THE PATENT COOPERATION TREATY
(PCT) |
|
|
|
|
|
|
(22) |
24 June 2003 (24.06.2003) |
|
|
(30) |
10/185,021 |
|
28 June 2002
(28.06.2002) |
|
US |
|
(43) |
08 January 2004 (08.01.2004) |
|
(54) |
DRUG-ELUTING STENTS
FOR TREATING VULNERABLE CORONARY PLAQUES |
|
(71) |
CORDIS CORPORATION
[US/US]; 1420 NW 60th Ave, Miami Lakes, FL 33014
(US). |
|
(72) |
FISCHELL, David, R.; 71
Riverlawn Drive, Fair Haven, NJ 07704 (US).
SPALTRO, John, J.; 12 Alpaugh Rd, Asbury, NJ
08802 (US). |
|
(74) |
JOHNSON, Philip, S., et al;
Johnson & Johnson, One Johnson & Johnson Plaza,
New Brunswick, NJ 08933 (US). |
|
(81) |
AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW |
|
(84) |
ARIPO patent (GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European patent (AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG) |
|
|
For information on time limits for entry into the
national phase please click here |
|
Published |
| -- |
with
international search report |
|
(88) |
01
April 2004 (01.04.2004) |
(57) A drug-eluting intravascular stent
comprising an anti-restenosis agent covered by a
biodegradable coating, and a method for treating
vulnerable plaque in coronary vessels using said
stent is disclosed. The biodegradable layer covers
at least a portion of the drug-eluting layer of the
stent, and is adapted to slowly erode over a preset
period of time, preventing the release of
therapeutic amounts of the anti-restenosis agent
from the drug-eluting layer during the preset
period. By delaying the release of the anti-restenosis
agent, a thin layer of neointima will grow during
the preset period. This tissue growth is sufficient
to encapsulate the stent and cover the vulnerable
plaque, but not significant enough to cause harmful
restenosis or occlusion of the vessel. Once the
biodegradable coating is eroded, the anti-restenosis
agent begins release from the drug-eluting layer,
and the progression of neointimal hyperplasia
ceases.
|
|
|
|